Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.

Jing LiaoDan-Ni ZengJin-Zhu LiQiao-Min HuaZhiyu XiaoChuanchao HeKai MaoLing-Yan ZhuYifan ChuWei-Ping WenLimin ZhengJing Liao

Published in: Hepatology international (2019)

These results suggest that adenosinergic pathway might represent an applicable target for sorafenib-combined-therapies in human HCC.

Keyphrases